Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $742.77 | 16 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $239.22 | 2 | $0 (2023) |
| Novo Nordisk Inc | $124.99 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $112.46 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $101.57 | 1 | $0 (2023) |
| Celgene Corporation | $84.00 | 4 | $0 (2024) |
| ABBVIE INC. | $43.32 | 2 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $37.21 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $335.44 | 10 | Novo Nordisk Inc ($124.99) |
| 2023 | $392.95 | 5 | Janssen Biotech, Inc. ($239.22) |
| 2021 | $14.38 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($14.38) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $30.12 | General |
| Category: Neuroscience | ||||||
| 08/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.33 | General |
| Category: Neuroscience | ||||||
| 07/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: IMMUNOLOGY | ||||||
| 06/03/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.33 | General |
| Category: Neuroscience | ||||||
| 05/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.21 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.22 | General |
| Category: Neuroscience | ||||||
| 01/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $89.28 | General |
| 01/09/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $35.71 | General |
| 01/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $32.95 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/23/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $33.94 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/19/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $118.08 | General |
| Category: Immunology | ||||||
| 07/26/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: IMMUNOLOGY | ||||||
| 03/27/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $101.57 | General |
| Category: Neuroscience | ||||||
| 03/21/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $121.14 | General |
| Category: Immunology | ||||||
| 10/25/2021 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 12 | $6,000 | $1,230 |
| 2022 | 1 | 13 | 13 | $6,500 | $1,382 |
| 2021 | 2 | 40 | 40 | $16,975 | $4,196 |
| 2020 | 1 | 26 | 26 | $11,700 | $1,581 |
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $6,000 | $1,230 | 20.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $6,500 | $1,382 | 21.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $11,025 | $2,795 | 25.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 17 | 17 | $5,950 | $1,401 | 23.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 26 | 26 | $11,700 | $1,581 | 13.5% |
About Anna Malouf, NP
Anna Malouf, NP is a Gerontology healthcare provider based in Framingham, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2013. The National Provider Identifier (NPI) number assigned to this provider is 1699115865.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Anna Malouf, NP has received a total of $742.77 in payments from pharmaceutical and medical device companies, with $335.44 received in 2024. These payments were reported across 16 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($742.77).
As a Medicare-enrolled provider, Malouf has provided services to 91 Medicare beneficiaries, totaling 91 services with total Medicare billing of $8,389. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Practice Information
- Specialty Gerontology
- Location Framingham, MA
- Active Since 07/02/2013
- Last Updated 01/02/2019
- Taxonomy Code 363LG0600X
- Entity Type Individual
- NPI Number 1699115865
Products in Payments
- STELARA (Biological) $239.22
- ZEPOSIA (Drug) $185.57
- ENTYVIO (Biological) $112.46
- RINVOQ (Biological) $43.32
- DUPIXENT (Biological) $37.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.